大剂量地塞米松冲击疗法及其在儿童免疫性血小板减少症中的应用  

Pulsed High-dose Dexamethasone Therapy and Its Application in Children with Immune Thrombocytopenia——Review

作　　者：傅玲玲[1] 吴润晖[1] 

机构地区：[1]首都医科大学附属北京儿童医院血液肿瘤中心,北京100045

出　　处：《中国实验血液学杂志》2016年第5期1598-1602,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金面上课题(81200351);北京市自然科学基金课题(7152053);北京市科技计划课题"首都临床特色应用研究"专项(Z141107002514130);北京市医院管理局临床医学发展专项(ZY2 01404);北京市卫生系统高层次卫生技术人才(2013-3-027)经费资助

摘　　要：免疫性血小板减少症(immune thrombocy topenia,ITP)是一种儿童最常见的免疫介导的获得性出血性疾病。大部分患儿近期可获得完全缓解,且预后良好,但仍有少数患儿对常规治疗无效,面临出血风险,需二线治疗的干预。然而现有的二线治疗,因为疗效、副作用和费用等因素不便广泛推广。大剂量地塞米松(high-dose dexame-thasone,HDD)冲击疗法因其在成人方面应用效果佳,不良反应小,费用低等因素,已作为初诊ITP患者的一线治疗,目前正逐步引起儿科医生的重视。本文就HDD冲击疗法在儿童ITP的应用最新进展作一综述。Immune thrombocytopenia（ITP） is the most common immune-mediated acquired bleeding disorders in children.The prognosis of majority of these patient are well,with recent complete remission.However,a few patients are facing the risk of bleeding since they do not respond to the first-line therapy,and need second-line therapy.The present second-line treatments are difficult to be popularized due to their efficacy,side-effects,costs and some other factors.The pulsed high-dose dexamethasone（HDD） therapy with its good effect,small adverse effects and low cost in adults has been used as the first-line therapy in newly diagnosed ITP,which now has attracted the attention of pediatricians.In this review,we briefly summarized the latest progress of pulsed HDD therapy for ITP in children.

关 键 词：免疫性血小板减少症 地塞米松 儿童 

分 类 号：R558.2[医药卫生—血液循环系统疾病]